SCHEMBL23969725

SCHEMBL23969725

CCc1c(Cl)c(O)c(F)c(Cl)c1Cl

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23867627 0.86 ESR1 (0.33) ESR1ESR2
SCHEMBL24870392 0.86
SCHEMBL23848699 0.86 ESR1 (0.33) ESR1ESR2
SCHEMBL23867631 0.82 ESR1 (0.33) ESR1ESR2
SCHEMBL24611067 0.82 HPGD (0.33)
SCHEMBL24462742 0.82 TSHR (0.39)
SCHEMBL24462739 0.78 HIF1A (0.34)
SCHEMBL23848773 0.78 IMPDH2 (0.31)
SCHEMBL23969727 0.77
SCHEMBL23867630 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213109-A1 KRAS mutant protein inhibitors JACOBIO PHARMACEUTICALS CO LTD (CN) 2022-07-07 US disclosed
US-11161847-B2 KRAS mutant protein inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2021-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11161847-B2 KRAS mutant protein inhibitors KRAS, NRAS, APC ESR1 2698/4885ESR2 3380/4885
US-20220213109-A1 KRAS mutant protein inhibitors KRAS, NRAS, APC ESR1 2781/4885ESR2 3425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.